Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease

Current Medical Research and Opinion

Volumn 20, Issue 6, 2004, Pages 931-938

  Monsch, Andreas U ^a   Giannakopoulos, Panteleimon ^b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Belle Idée   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Acetylcholinesterase inhibition; Alzheimer's disease; Behavioural disturbances; Caregiver burden; Dementia; Galantamine; Nicotinic receptors

Indexed keywords

GALANTAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; CAREGIVER; CLINICAL TRIAL; COGNITION; DELUSION; DIARRHEA; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; SWITZERLAND; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; FEMALE; GALANTAMINE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NOOTROPIC AGENTS; SWITZERLAND;

EID: 3042642016     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003890     Document Type: Article

References (45)

1. Cummings JL, McPherson S. Neuropsychiatric assessment of Alzheimer's disease and related dementias. Aging 2001;13(3):240-6
2. Durand PJ, Krueger PD, Chambers LW, Grek A, Charles C. Predictors of caregivers' dissatisfaction with community long-term care services for seniors: results from the Canadian Study of Health and Aging (CSHA). Can J Public Health 1995;86:325-32
3. Cummings J. Cholinesterase inhibitors: expanding applications. Lancet 2000;356:2024-5
4. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group. A 24-week, randomised, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-20
5. Tariot PN, Cummings JL, Katz IR, et al. A randomised double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-9
6. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomised, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76
7. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet 2002;359:1283-90
8. Roesler M, Retz W, Retz-Jungingen P, Dennler HJ. Effects of two-year treatment with cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1999;11:211-6
9. Bullock R et al. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer's disease. Int Psychogeriatr 2001;13(Suppl 2):242
10. Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995;64:385-95
11. Fu Y, Matta SG, Gao W, Sharp BM. Local α-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo. Neuroscience 2000;101(2):369-75
12. Court JA, Piggott MA, Lloyd S, et al. Nicotinic binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 2000;98(1):79-87
13. Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol 2002;53:641-55
14. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002;53:590-605
15. Berg DK, Conroy WG. Nicotinic α-7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 2002;53:512-23
16. Pereira EFR, Hilmas C, Santos MD, Alkondon M, Maelicke A, Albuquerque EX. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 2002;53:479-500
17. Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117-36
18. Alkondon M, Braga MF, Pereira EF, Maelicke A, Albuquerque EX. α7-Nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol 2000;393:59-67
19. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000;20:66-75
20. Santos MD, Alkondon M, Pereira EFR, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammelian central nervous system. Mol Pharmacol 2002;61:1222-34
21. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001;49:279-88
22. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dementia Geriatr Cogn Disord 2000;11(Suppl 1):11-8
23. Lazarewicz M, Spiros A, Finkel L, Carr R, Geerts H. The virtual synaptic cleft model, 2001 [data on file]. Understanding the cholinergic effects of reminyl using a virtual synaptic cleft. The International Conference on Alzheimer's Disease and Related Disorders, Stockholm, 2002
24. Spiros A, Lazarewicz MT, Zhang L, et al. Galantamine increases dopamine output: insights using a virtual cross-talk model. 1CAD 2002. Poster presentation. The International Conference on Alzheimer's Disease and Related Disorders, Stockholm, 2002
25. Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000;20:1208-15
26. Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 2001;12:4121-5
27. Labarca C, Schwarz J, Deshpande P, et al. Point mutant mice with hypersensitive α4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci, USA 2001;98:2786-91
28. Raskind MA, Peskind E, Wessel T, Yuan W, The Galantamine USA-1 Study Group. Galantamine in AD: a 6-month, randomised, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8
29. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicenter randomised controlled trial. Br Med J 2000;321:1445-8
30. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95
31. Erkinjuntti T, Lilienfeld S. Galantamine demonstrates broad clinical efficacy over 12 months in patients with Alzheimer's disease with cerebrovascular disease and probable vascular dementia. [AAN 2002; Poster presentation]. Neurology 2002;58(7, Suppl 3):278 [poster P04.047]
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA Work Group* under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-44
33. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
34. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study - clinical global impression of change. Alzheimer Dis Assoc Disord 1997;1(Suppl 2):22-32
35. Brunner C, Spiegel R. Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for GERiatric Patients), einem neuen Beurteilungsinstrument fuer die Psychogeriatrie. Z Klin Psychol 1990;19:211-29
36. Folstein MF, Flstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
37. WHO 1CD-10 classification of mental and behavioural disorders. Geneva: World Health Organization; 1992
38. Lang CJG, Hager K, Roesler M, Rettig K, Schwalen S. Cognitive and behavioural benefits with 6 months of galantamine (Reminyl) treatment in patients with mild Alzheimer's disease results in reduced caregiver stress. 1CAD 2002; [Poster presentation]
39. Robert Ph. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002;18:156-71
40. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95
41. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15
42. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Soc Biol Psychiatry 2001;49:166-74
43. Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol 2002;88:133-8
44. Greene JG, Smith R, Gardiner M, Timbury GC. Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing 1982;11:121-6
45. Pang FC, Chow TW, Cummings JL, et al. Effect of neuropsychiatric symptoms of Alzheimer's disease on Chinese and American caregivers. Int J Geriatr Psychiatry 2002;17(1):29-34